Lifeward Secures Humana Approval for ReWalk 7 Exoskeleton

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Dec 03 2025

0mins

LFWD+4.97%

Should l Buy LFWD?

Source: Newsfilter

Market Leadership: Lifeward's approval from Humana Medicare Advantage Plan enables nearly half of all Medicare Advantage enrollees to access the ReWalk 7 exoskeleton, further solidifying its leadership position in the medical technology sector.
Revenue Growth Potential: This approval is expected to enhance Lifeward's revenue and cash flow dynamics, thereby establishing a stronger foundation for sustainable growth in the U.S. market.
Promotion of Innovative Technology: Humana's endorsement reflects its commitment to supporting innovative medical technologies aimed at providing more reliable exoskeleton solutions for spinal cord injury patients, thereby improving their quality of life.
Accelerated Payer Adoption: As coverage for the ReWalk exoskeleton expands, Lifeward is experiencing a faster pace of prior authorization approvals, which not only increases reimbursement predictability but also creates favorable conditions for the company's future market expansion.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy LFWD?" and start using high-conviction signals backed by rigorous historical data.

LFWD

$0.57+Infinity%1D

Analyst Views on LFWD

Wall Street analysts forecast LFWD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFWD is 4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.543

Low

4.50

Averages

4.50

High

4.50

Current: 0.543

Low

4.50

Averages

4.50

High

4.50

H.C. Wainwright

Swayampakula Ramakanth

Buy

downgrade

$13

2025-11-18

Reason

H.C. Wainwright

Swayampakula Ramakanth

Price Target

$13

AI Analysis

2025-11-18

downgrade

Buy

Reason

H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm's price target on Lifeward to $4.50 from $13 and keeps a Buy rating on the shares following the Q3 report. The firm says the company's operational changes, regulatory wins and changes in payor dynamics underway bode well for future growth.

Lake Street

Ben Haynor

Strong Buy

Maintains

$4.5 → $4

2025-03-11

Reason

Lake Street

Ben Haynor

Price Target

$4.5 → $4

2025-03-11

Maintains

Strong Buy

Reason

About LFWD

Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million

Jan 13 2026NASDAQ.COM

Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.

Lifeward Appoints Bob Marshall as Chairman of the Board Effective January 1, 2026

Dec 19 2025Globenewswire

Leadership Transition: Lifeward announces the appointment of Bob Marshall as the new Chairman of the Board effective January 1, 2026, succeeding Joseph Turk, who will take on the role of CEO at Fresenius Medical Care, indicating stability and strategic continuity during executive transitions.
Financial Leadership Experience: Bob Marshall has been a board member and Chair of the Audit Committee since 2024, and his extensive financial leadership experience as CFO at Lantheus Holdings is expected to provide crucial support for Lifeward's strategic growth plans.
Strategic Growth Plans: Lifeward's CEO Mark Grant emphasizes that Marshall's addition will enhance the company's innovation and development in medical technology, driving improvements in patient care and outcomes, thereby further solidifying its market position.
Industry Background: Marshall's 16 years of experience at Zimmer Biomet Holdings will bring valuable industry insights to Lifeward, aiding the company in achieving sustainable growth in a competitive market.

Lifeward Appoints Bob Marshall as Chairman of the Board Effective January 1, 2026

Dec 19 2025Newsfilter

Leadership Transition: Lifeward has announced the appointment of Bob Marshall as the new Chairman of the Board effective January 1, 2026, succeeding Joseph Turk, who will take on the role of CEO at Fresenius Medical Care, indicating a strategic shift in the company's executive leadership.
Experienced Successor: Bob Marshall has been a board member since 2024 and served as Chair of the Audit Committee, and his financial leadership and expertise in the healthcare public company sector are expected to significantly support Lifeward's strategic growth plans, enhancing its competitive edge in the medical technology field.
Contribution of Predecessor: Joseph Turk's leadership has driven the company's development, and the board expressed gratitude for his contributions during his tenure, reflecting the company's commitment to leadership stability, which is crucial for maintaining investor confidence.
Future Outlook: The appointment of the new chairman aligns with Lifeward's long-term strategic goals, aiming to improve patient care and outcomes through ongoing innovation and market expansion, thereby further solidifying its leadership position in the medical technology sector.

Lifeward Partners with Verita Neuro to Expand ReWalk Market Access

Dec 17 2025Newsfilter

Market Expansion: Lifeward's international distribution agreement with Singapore's Verita Neuro aims to promote the ReWalk Personal Exoskeleton in Mexico, Thailand, and the UAE, potentially reaching over 25,000 spinal cord injury patients and significantly enhancing global market penetration.
Innovative Delivery Model: The new agreement integrates ReWalk into Verita's multi-modal treatment protocols, with personalized setup and training in inpatient rehabilitation programs expected to accelerate clinical adoption and improve patient recovery outcomes.
Market Potential: With over 7 million spinal cord injury survivors globally, Lifeward's total addressable market for ReWalk is estimated at $1.75 billion, indicating substantial growth potential in the medical technology sector.
Strategic Alignment: This partnership complements Lifeward's existing distribution and reimbursement networks in the U.S. and Germany, aiming to drive long-term sustainable growth through a capital-efficient collaborative model that enhances the company's competitive edge in international markets.